The Role Of Progestogens In Threatened And Idiopathic Recurrent Miscarriage

References

• Macklon NS, Geraedts JP, Fauser BC. Conception to ongoing pregnancy: the ‘black box’ of early pregnancy loss. Hum Reprod Update. 2002;8(4):333–343. doi:10.1093/humupd/8.4.33312206468
   PubMed Web of Science ®Google Scholar
• Larsen EC, Christiansen OB, Kolte AM, Macklon N. New insights into mechanisms behind miscarriage. BMC Med. 2013;11:154. doi:10.1186/1741-7015-11-15423803387
   PubMed Web of Science ®Google Scholar
• Griebel CP, Halvorsen J, Golemon TB, Day AA. Management of spontaneous abortion. Am Fam Physician. 2005;72(7):1243–1250.16225027
   PubMed Web of Science ®Google Scholar
• Zhang HX, Qin YZ, Liu WH, Hao R. Hypothyroidism and first-trimester spontaneous miscarriages. Clin Exp Obstet Gynecol. 2014;41(2):182–185.24779248
   PubMed Web of Science ®Google Scholar
• Chang K, Lubo Z. Review article: steroid hormones and uterine vascular adaptation to pregnancy. Reprod Sci. 2008;15(4):336–348. doi:10.1177/193371910831797518497342
   PubMed Web of Science ®Google Scholar
• Di Renzo GC, Giardina I, Clerici G, Brillo E, Gerli S. Progesterone in normal and pathological pregnancy. Horm Mol Biol Clin Investig. 2016;27(1):35–48. doi:10.1515/hmbci-2016-0038
   PubMed Web of Science ®Google Scholar
• Czyzyk A, Podfigurna A, Genazzani AR, Meczekalski B. The role of progesterone therapy in early pregnancy: from physiological role to therapeutic utility. Gynecol Endocrinol. 2017;33(6):421–424. doi:10.1080/09513590.2017.129161528277122
   PubMed Web of Science ®Google Scholar
• Raghupathy R, Al Mutawa E, Makhseed M, Azizieh F, Szekeres-Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG. 2005;112(8):1096–1101. doi:10.1111/j.1471-0528.2005.00633.x16045524
   PubMed Web of Science ®Google Scholar
• Mincheva-Nilsson L. Pregnancy and gamma/delta T cells: taking on the hard questions. Reprod Biol Endocrinol. 2003;1:120. doi:10.1186/1477-7827-1-12014651751
   PubMedGoogle Scholar
• ESHRE Early Pregnancy Guidline Development Group. Recurrent pregnancy loss. Guideline of the European Society of Human Reproduction and Embryology. Available from: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx Accessed 10, 152018.
   Google Scholar
• Arab H, Alsofayan H, Alharbi A, Sendy S, Abduljabbar H; The Saudi Obstetrics and Gynecological Society (SOGS). National guidelines for the prevention and treatment of miscarriage. Saudi J Obstet Gynecol. 2014;15(1):40–63.
   Google Scholar
• Pustotina O. Effectiveness of dydrogesterone, 17-OH progesterone and micronized progesterone in prevention of preterm birth in women with a short cervix. J Matern Fetal Neonatal Med. 2018;31(14):1830–1838. doi:10.1080/14767058.2017.133040628502186
   PubMed Web of Science ®Google Scholar
• Kececioglu M, Tokmak A, Kececioglu TS, Akselim B, Karakaya BK, Tasci Y. Does progesterone therapy increase nuchal translucency in women with threatened miscarriage? Ginekol Pol. 2016;87(5):390–394. doi:10.5603/GP.2016.001027304657
   PubMed Web of Science ®Google Scholar
• Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet. 2009;104(1):40–43. doi:10.1016/j.ijgo.2008.08.02918929360
   PubMed Web of Science ®Google Scholar
• Glover MM, McKenna DS, Downing CM, Smith DB, Croom CS, Sonek JD. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol. 2011;28(5):377–381. doi:10.1055/s-0031-127450921380990
   PubMed Web of Science ®Google Scholar
• Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol. 2012;28(12):983–990. doi:10.3109/09513590.2012.70287522794306
   PubMed Web of Science ®Google Scholar
• Lee HJ, Park TC, Kim JH, Norwitz E, Lee B. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: a systematic review and meta-analysis. Biomed Res Int. 2017;2017:3616875. doi:10.1155/2017/361687529392134
   PubMed Web of Science ®Google Scholar
• Wang XX, Luo Q, Bai WP. Efficacy of progesterone on threatened miscarriage: difference in drug types. J Obstet Gynaecol Res. 2019;45(4):794–802. doi:10.1111/jog.1390930632226
   PubMed Web of Science ®Google Scholar
• Wahabi HA, Fayed AA, Esmaeil SA, Bahkali KH. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2018;8:CD005943.30081430
   PubMed Web of Science ®Google Scholar
• El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas. 2009;65 Suppl 1:S43–S46. doi:10.1016/j.maturitas.2009.11.01320007011
   PubMed Web of Science ®Google Scholar
• Siew JYS, Allen JC, Hui CYY, et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol. 2018;228:319–324. doi:10.1016/j.ejogrb.2018.07.02830077119
   PubMed Web of Science ®Google Scholar
• Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol. 2005;97(5):421–425. doi:10.1016/j.jsbmb.2005.08.01316293412
   PubMed Web of Science ®Google Scholar
• Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009;65(Suppl 1):S47–S50. doi:10.1016/j.maturitas.2009.11.01620005647
   PubMed Web of Science ®Google Scholar
• Carp H. A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol. 2015;31(6):422–430. doi:10.3109/09513590.2015.100661825765519
   PubMed Web of Science ®Google Scholar
• Saccone G, Schoen C, Franasiak JM, Scott RT Jr., Berghella V. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 2017;107(2):430–438 e433. doi:10.1016/j.fertnstert.2016.10.03127887710
   PubMed Web of Science ®Google Scholar
• Kumar A, Begum N, Prasad S, Aggarwal S, Sharma S. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril. 2014;102(5):1357–1363 e1353. doi:10.1016/j.fertnstert.2014.07.125125241364
   PubMed Web of Science ®Google Scholar
• El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol. 2005;97(5):431–434. doi:10.1016/j.jsbmb.2005.08.00716253504
   PubMed Web of Science ®Google Scholar
• Yassaee F, Shekarriz-Foumani R, Afsari S, Fallahian M. The effect of progesterone suppositories on threatened abortion: a randomized clinical trial. J Reprod Infertil. 2014;15(3):147–151.25202672
   PubMedGoogle Scholar
• Palagiano A, Bulletti C, Pace MC, DEZ D, Cicinelli E, Izzo A. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann N Y Acad Sci. 2004;1034:200–210. doi:10.1196/annals.1335.02215731312
   PubMed Web of Science ®Google Scholar
• Coomarasamy A, Devall AJ, Cheed V, et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N Engl J Med. 2019;380(19):1815–1824. doi:10.1056/NEJMoa181373031067371
   PubMed Web of Science ®Google Scholar
• Coomarasamy A, Williams H, Truchanowicz E, et al. PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages – a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation. Health Technol Assess. 2016;20(41):1–92. doi:10.3310/hta20410
   Web of Science ®Google Scholar
• Ismail AM, Abbas AM, Ali MK, Amin AF. Peri-conceptional progesterone treatment in women with unexplained recurrent miscarriage: a randomized double-blind placebo-controlled trial. J Matern Fetal Neonatal Med. 2018;31(3):388–394. doi:10.1080/14767058.2017.128631528114846
   PubMed Web of Science ®Google Scholar
• Haas DM, Hathaway TJ, Ramsey PS. Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology. Cochrane Database Syst Rev. 2018;10:CD003511.30298541
   PubMed Web of Science ®Google Scholar
• Schindler AE, Carp H, Druckmann R, et al. European progestin club guidelines for prevention and treatment of threatened or recurrent (habitual) miscarriage with progestogens. Gynecol Endocrinol. 2015;31(6):447–449. doi:10.3109/09513590.2015.101745925976550
   PubMed Web of Science ®Google Scholar
• Toth B, Wurfel W, Bohlmann M, et al. Recurrent miscarriage: diagnostic and therapeutic procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050). Geburtshilfe Frauenheilkd. 2018;78(4):364–381. doi:10.1055/a-0586-456829720743
   PubMed Web of Science ®Google Scholar
• Saccone G, Khalifeh A, Elimian A, et al. Vaginal progesterone vs intramuscular 17alpha-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2017;49(3):315–321. doi:10.1002/uog.1724527546354
   PubMed Web of Science ®Google Scholar
• Samson FD, Merriman AL, Tate DL, Apostolakis-Kyrus K, Gomez LM. Adjuvant administration of 17-alpha-hydroxy-progesterone caproate in women with three or more second trimester pregnancy losses undergoing cervical cerclage is no more effective than cerclage alone. J Perinat Med. 2018;46(2):155–161. doi:10.1515/jpm-2017-007428753545
   PubMed Web of Science ®Google Scholar
• Duan L, Yan D, Zeng W, Yang X, Wei Q. Effect of progesterone treatment due to threatened abortion in early pregnancy for obstetric and perinatal outcomes. Early Hum Dev. 2010;86(1):41–43. doi:10.1016/j.earlhumdev.2009.12.00720079582
   PubMed Web of Science ®Google Scholar
• Haghighi L, Rashidi M, Najmi Z, et al. Comparison of intramuscular progesterone with oral nifedipine for treating threatened preterm labor: a randomized controlled trial. Med J Islam Repub Iran. 2017;31:56. doi:10.14196/mjiri.31.5629445685
   PubMedGoogle Scholar
• Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994;62(3):485–490. doi:10.1016/s0015-0282(16)56935-08062942
   PubMed Web of Science ®Google Scholar
• Smitz J, Devroey P, Faguer B, Bourgain C, Camus M, Van Steirteghem AC. A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum Reprod. 1992;7(2):168–175. doi:10.1093/oxfordjournals.humrep.a1376111577927
   PubMed Web of Science ®Google Scholar
• Sohn SH, Penzias AS, Emmi AM, et al. Administration of progesterone before oocyte retrieval negatively affects the implantation rate. Fertil Steril. 1999;71(1):11–14. doi:10.1016/s0015-0282(98)00404-x9935109
   PubMed Web of Science ®Google Scholar
• Beigi A, Esmailzadeh A, Pirjani R. Comparison of risk of preterm labor between vaginal progesterone and 17-alpha-hydroxy-progesterone caproate in women with threatened abortion: a randomized clinical trial. Int J Fertil Steril. 2016;10(2):162–168.27441048
   PubMedGoogle Scholar
• Wetendorf M, DeMayo FJ. Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus. Int J Dev Biol. 2014;58(2–4):95–106. doi:10.1387/ijdb.140069mw25023675
   PubMed Web of Science ®Google Scholar
• Carranza-Lira S, Blanquet J, Tserotas K, Calzada L. Endometrial progesterone and estradiol receptors in patients with recurrent early pregnancy loss of unknown etiology–preliminary report. Med Sci Monit. 2000;6(4):759–762.11208405
   PubMedGoogle Scholar
• DeMayo FJ, Zhao B, Takamoto N, Tsai SY. Mechanisms of action of estrogen and progesterone. Ann N Y Acad Sci. 2002;955:48–59. doi:10.1111/j.1749-6632.2002.tb02765.x11949965
   PubMed Web of Science ®Google Scholar
• Lucovnik M, Kuon RJ, Chambliss LR, et al. Progestin treatment for the prevention of preterm birth. Acta Obstet Gynecol Scand. 2011;90(10):1057–1069. doi:10.1111/j.1600-0412.2011.01178.x21564026
   PubMed Web of Science ®Google Scholar
• Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A, Group P. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol. 2011;38(3):272–280. doi:10.1002/uog.909321739497
   PubMed Web of Science ®Google Scholar
• Goletiani NV, Keith DR, Gorsky SJ. Progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol. 2007;15(5):427–444. doi:10.1037/1064-1297.15.5.42717924777
   PubMed Web of Science ®Google Scholar
• Tournaye H, Sukhikh GT, Kahler E, Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017;32(5):1019–1027. doi:10.1093/humrep/dex02328333318
   PubMed Web of Science ®Google Scholar
• Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev. 2009;85(6):375–377. doi:10.1016/j.earlhumdev.2008.12.01619193503
   PubMed Web of Science ®Google Scholar
• Arab HA. An insight into early fetal loss. Obstet Gynecol. 2017;1(2):67–69.
   Google Scholar
• Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379–2385. doi:10.1056/NEJMoa03514012802023
   PubMed Web of Science ®Google Scholar
• Carmichael SL, Shaw GM, Laurent C, Croughan MS, Olney RS, Lammer EJ. Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med. 2005;159(10):957–962. doi:10.1001/archpedi.159.10.95716203941
   PubMedGoogle Scholar
• Check JH, Rankin A, Teichman M. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil Steril. 1986;45(4):575–577. doi:10.1016/s0015-0282(16)49292-73956772
   PubMed Web of Science ®Google Scholar
• Rock JA, Wentz AC, Cole KA, et al. Fetal malformations following progesterone therapy during pregnancy: a preliminary report. Fertil Steril. 1985;44(1):17–19. doi:10.1016/s0015-0282(16)48670-x4007191
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive M. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril. 2008;89(4):789–792. doi:10.1016/j.fertnstert.2008.02.01218406835
   PubMed Web of Science ®Google Scholar
• Rizner TL, Brozic P, Doucette C, et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011;76(6):607–615. doi:10.1016/j.steroids.2011.02.04321376746
   PubMed Web of Science ®Google Scholar
• Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2011;(12):CD005943.
   Web of Science ®Google Scholar